J0702 HCPCS code: Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
J0702 is the HCPCS Level II code for injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg. In 2024 Medicare paid an average of $5.18 per service for J0702 across 2,154,508 services. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met. The NCCI unit limit is 20 per day on outpatient hospital claims. Medicare volume fell 14% from 2022 to 2024 (2,491,252 to 2,154,508 services). In 2024, about 18,842 clinicians billed Medicare for J0702 for 592,568 beneficiaries; Florida, Pennsylvania, California accounted for 22% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 1995-01-01 |
| Last action effective | 2008-01-01 |
Who bills J0702 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 18,842 |
| Medicare beneficiaries | 592,568 |
| States with claims | 53 |
| Share of services in top 3 states (Florida, Pennsylvania, California) | 22% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J0702, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 2,491,252 | 659,173 | $6.58 | $4.94 |
| 2023 | 2,256,690 | 615,824 | $6.50 | $4.88 |
| 2024 | 2,154,508 | 592,568 | $6.90 | $5.18 |
States with the most J0702 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 191,066 | $5.30 |
| Pennsylvania | 154,504 | $5.19 |
| California | 130,643 | $5.33 |
| North Carolina | 110,322 | $5.21 |
| New York | 102,985 | $5.38 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 20 | Clinical: Data |
| practitioner claims | 18 | Clinical: Data |
Medicare policy articles for this code
- A57114: Billing and Coding: Trigger Point Injections (First Coast Service Options, Inc. (MAC - Part B))
- A57751: Billing and Coding: Trigger Point Injections (Novitas Solutions, Inc. (MAC - Part A, MAC - Part B))
Covered diagnoses (2 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| M79.12 | Myalgia of auxiliary muscles, head and neck | 2 |
| M79.18 | Myalgia, other site | 2 |
What changed for J0702
- 1995-01-01: J0702 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J0702?
J0702 is the HCPCS Level II code for injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg. Short descriptor: "Betamethasone acet&sod phosp".
How much does Medicare pay for J0702?
In 2024, the average Medicare payment was $5.18 per service (average allowed $6.90).
Does Medicare cover J0702?
Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.
Which diagnoses support coverage for J0702?
Medicare policy articles that cite J0702 list 2 covered ICD-10-CM diagnosis codes across 2 articles. The most cited include M79.12 (Myalgia of auxiliary muscles, head and neck), M79.18 (Myalgia, other site). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J0702 can be billed per day?
20 on outpatient hospital claims; 18 on practitioner claims (NCCI medically unlikely edits).
Related J07 codes
- J0701 — Injection, cefepime hydrochloride (baxter), not therapeutically equivalent to maxipime, 500 mg
- J0703 — Injection, cefepime hydrochloride (b braun), not therapeutically equivalent to maxipime, 500 mg
- J0706 — Injection, caffeine citrate, 5 mg
- J0710 — Injection, cephapirin sodium, up to 1 gm
- J0712 — Injection, ceftaroline fosamil, 10 mg
- J0713 — Injection, ceftazidime, per 500 mg
- J0714 — Injection, ceftazidime and avibactam, 0.5 g/0.125 g
- J0715 — Injection, ceftizoxime sodium, per 500 mg
- J0716 — Injection, centruroides immune f(ab)2, up to 120 milligrams
- J0717 — Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
- J0720 — Injection, chloramphenicol sodium succinate, up to 1 gm
- J0725 — Injection, chorionic gonadotropin, per 1,000 usp units
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J0702
- Watch J0702 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J0702
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.